Showing 5721-5730 of 8159 results for "".
- Ortho Dermatologics Launches Telemedicine on Dermatology.com, US Cash-Pay Prescription Programhttps://practicaldermatology.com/news/ortho-dermatologics-launches-telemedicine-on-dermatologycom-us-cash-pay-prescription-program/2460285/
- Defective Stem Cell Behavior Linked to Psoriasishttps://practicaldermatology.com/news/defective-stem-cell-behavior-linked-to-psoriasis/2460233/Investigators from
- Daily Almond Consumption May Reduce Facial Wrinkleshttps://practicaldermatology.com/news/daily-almond-consumption-may-reduce-facial-wrinkles/2460165/Snacking on almonds may help postmenopausal women smooth wrinkles from the inside out, according to a new study funded by the Almond Board of California. In this 16-week randomized controlled trial, 28 healthy
- With New Funding, Turn Therapeutics Will Launch Phase 4 Study of AD Drughttps://practicaldermatology.com/news/with-new-funding-turn-therapeutics-will-launch-phase-4-study-of-ad-drug/2460162/Turn Therapeutics has closed its fully-subscribed series B financing. The capital raised will fund a large-scale, pre-launch, phase 4 trial for AtopX Eczema Emulsion, with enrollment scheduled to begin in Q1 2020. The series B financing will also support advancement of additional i
- Neutrogena’s Newest Collection Addresses Dull, Uneven Skinhttps://practicaldermatology.com/news/neutrogenas-newest-collection-addresses-dull-uneven-skin/2460157/Nearly two-thirds (66 percent) of U.S. millennial women age 23-38 have noticed a shift in their skin's brightness, according to a poll of more 1,100 U.S. women aged 18 and older sponsored by Neutrogena. Neutrogena’s new four-part collection,
- Aczone 7.5% Gel Now Approved Down to Age 9https://practicaldermatology.com/news/aczone-75-gel-now-approved-down-to-age-9/2460144/The FDA has approved the expanded indication for Almirall’s Aczone® 7.5% Gel to include patients aged 9-11. Aczone 7.5% Gel was previously approved in February 2016 to treat inflammatory and non-inflammatory acne in patients 12 and older. The expanded approval was based
- Summer AAD News: Understanding the Dermatologist’s Role in Reducing Skin-related Side Effects from New Cancer Drugshttps://practicaldermatology.com/news/summer-aad-news-understanding-the-dermatologists-role-in-reducing-skin-related-side-effects-from-new-cancer-drugs/2460107/While a new wave of targeted therapies are helping patients fight cancer, they also produce side effects that can affect patients’ hair, skin and nails that can greatly impact patients’ quality of life and threaten their ability to continue treatment. “Approximat
- Data Show 2-Year Complete Response with AbbVie's Skyrizi: WCDhttps://practicaldermatology.com/news/data-show-2-year-complete-response-with-abbvies-skyrizi-wcd/2460064/New results presented by AbbVie show that a significant number of patients treated with Skyrizi™ (risankizumab) experienced complete skin clearance at week 94. These two-year results (up to 104 weeks) from the Phase 3 IMMhance study, evaluating the efficacy and safety of SKYRIZI in adu
- Homemade Sunscreens Shared on Pinterest May Do More Harm than Goodhttps://practicaldermatology.com/news/homemade-sunscreens-shared-on-pinterest-may-do-more-harm-than-good/2460035/Nearly all—95 percent—of pins for homemade sunscreen found on Pinterest positively portrayed the effectiveness of the sunscreen and most—68 percent—recommended recipes for homemade sunscreens that offered insufficient UV protection, according to a
- BTL HIFEM Devices Honored by Harper's Bazaar, NewBeautyhttps://practicaldermatology.com/news/btl-hifem-devices-honored-by-harpers-bazaar-newbeauty/2459976/BTL has received two new accolades from NewBeauty and Harper's Bazaar